KEYTRUDA® (Pembrolizumab)

The FDA on May 23, 2017 granted accelerated approval to KEYTRUDA® for adult and pediatric patients with unresectable or metastatic, MicroSatellite Instability-High (MSI-H) or MisMatch Repair deficient (dMMR) solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options or with MSI-H or dMMR ColoRectal Cancer that has progressed following treatment with a Fluoropyrimidine, Oxaliplatin, and Irinotecan. KEYTRUDA® is a product of Merck and Co., Inc.